CASI Pharmaceuticals, Inc. (NASDAQ:CASI)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Friday. They presently have a $2.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 81.82% from the company’s current price.

Several other research firms have also recently issued reports on CASI. Maxim Group set a $4.00 target price on CASI Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, May 16th. ValuEngine raised CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th.

Shares of CASI Pharmaceuticals (NASDAQ CASI) traded down 9.09% during trading on Friday, reaching $1.00. The company’s stock had a trading volume of 29,889 shares. CASI Pharmaceuticals has a 1-year low of $0.91 and a 1-year high of $1.76. The stock has a 50 day moving average of $1.00 and a 200-day moving average of $1.13. The company’s market capitalization is $60.20 million.

CASI Pharmaceuticals (NASDAQ:CASI) last posted its earnings results on Monday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.01. On average, analysts expect that CASI Pharmaceuticals will post ($0.15) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Receive News & Stock Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.